Trivium Point Advisory LLC Purchases Shares of 5,457 Guardant Health, Inc. $GH

Trivium Point Advisory LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, Holdings Channel reports. The firm purchased 5,457 shares of the company’s stock, valued at approximately $819,000.

Other large investors have also made changes to their positions in the company. Global Retirement Partners LLC acquired a new stake in Guardant Health during the second quarter worth $59,000. State of Wyoming bought a new stake in Guardant Health in the 2nd quarter valued at $393,000. GSA Capital Partners LLP acquired a new position in shares of Guardant Health in the 2nd quarter valued at $1,772,000. SWS Partners acquired a new position in shares of Guardant Health in the 2nd quarter valued at $11,190,000. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Guardant Health by 159.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company’s stock worth $45,165,000 after acquiring an additional 185,200 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $157.21 on Monday. The stock has a market capitalization of $21.10 billion, a price-to-earnings ratio of -45.05 and a beta of 1.60. The firm’s 50-day moving average price is $150.40 and its two-hundred day moving average price is $116.89. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58.

Analyst Ratings Changes

Several brokerages have recently weighed in on GH. Stifel Nicolaus lifted their target price on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group increased their price target on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Barclays raised their price target on shares of Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Citigroup upped their price objective on Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Mizuho increased their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Insider Buying and Selling at Guardant Health

In related news, insider Chris Freeman sold 63,605 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the transaction, the insider owned 65,374 shares in the company, valued at $11,086,122.92. This represents a 49.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the sale, the insider directly owned 22,979 shares in the company, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 784,234 shares of company stock worth $106,493,352 over the last quarter. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.